Skip to content

Efficacy and side effects of different doses of Tripterygium Wilfordii Granules combined with traditional chinese medicine in the treatment of children with recurrent Henoch-Schonlein Purpura

Efficacy and side effects of different doses of Tripterygium Wilfordii Granules combined with traditional chinese medicine in the treatment of children with recurrent Henoch-Schonlein Purpura

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050353
Enrollment
Unknown
Registered
2021-08-26
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Henoch-Schonlein purpura

Interventions

Sponsors

The First Affilitated Hospital of He'nan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 16 Years

Inclusion criteria

Inclusion criteria: 1. Meet Western medical diagnostic criteria for Henoch-Schonlein purpura; 2. Aged 3 to 16 years; 3. With 3 or more recurrent episodes of rash with a duration of illness greater than 2 weeks; 4. Chinese medicine classification is blood-heat delusion; 5. The child and the child's family agree and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. With severe gastrointestinal symptoms or kidney damage; 2. With primary cardiovascular, hepatic, renal, hematopoietic, psychiatric and neurological diseases, decreased white blood cells and elevated liver enzymes; 3. Suffering from other acute and chronic diseases at the same time (e.g. immunodeficiency diseases).

Design outcomes

Primary

MeasureTime frame
Rash remission time;

Secondary

MeasureTime frame
Quantitative points for TCM symptoms;

Countries

China

Contacts

Public ContactDing Ying

He'nan University of Traditional Chinese Medicine

dingying3236@sina.com+86 13503840642

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026